BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, and CELLforCURE, part of France's SEQENS Group, have announced a strategic partnership to support the development and large-scale production of Advanced Therapy Medicinal Products (ATMPs). The collaboration establishes a transatlantic manufacturing network that enables companies on both sides of the Atlantic to access expanded production capabilities for cell and gene therapies.
Bridging Manufacturing Capacity Across Continents
The partnership creates a bidirectional manufacturing solution where U.S. companies can leverage CELLforCURE's European manufacturing capabilities, while European companies gain access to BBG Advanced Therapies' production capacities in the United States. This arrangement provides enhanced global Contract Development and Manufacturing Organization (CDMO) capacity and an integrated service network to support ATMP developers throughout their product lifecycle.
According to the companies, this collaboration creates a fully scalable, global CDMO partnership that accelerates the journey from concept to commercialization by combining transatlantic expertise and infrastructure. The partnership enables therapy developers to scale rapidly, launch multinational trials, and reach patients more effectively.
Complementary Manufacturing Capabilities
BBG Advanced Therapies brings extensive cell and tissue expertise with cutting-edge biomanufacturing capabilities to the partnership. The company maintains a strong track record in mesenchymal stem cell (MSC)-based projects and adheres to FDA, EMA, and PMDA regulations. BBGAT's comprehensive service ecosystem spans leukapheresis, donor management, testing, cryopreservation, and assay development, all operating under a unified Quality Management System.
The company's manufacturing infrastructure includes 9 cGMP cleanrooms spanning over 558 square meters (6,000 square feet) and a process development space covering over 232 square meters (2,500 square feet). Notably, BBGAT operates the world's only mobile leukapheresis center, demonstrating its commitment to advancing industry capabilities and expanding patient access.
CELLforCURE contributes significant manufacturing scale and regulatory compliance to the partnership. The EMA-authorized and FDA-compliant facility operates as a "one-stop-shop" spanning 10,000 square meters, including 3,000 square meters (32,291 square feet) of GMP-certified areas. The facility features 7 independent manufacturing lines, each equipped with 8 cleanrooms, ensuring maximum safety and compliance for every product.
Specialized Expertise in Advanced Therapies
CELLforCURE has established a strong track record in CAR-T manufacturing and immune cell therapies, positioning itself as a comprehensive solution provider for advanced therapies. The company enables seamless project development by leveraging in-house Quality Control for 90% of processes, ensuring high-quality drug product delivery from Phase I through full-scale commercial production.
BBG Advanced Therapies supports innovators progressing from early-stage development through late-phase readiness and market launch. The company's holistic approach encompasses collection and processing of starting materials, testing, clinical trials support, and biomanufacturing services, providing a fully integrated portfolio of solutions for cell and gene therapy development.
Strategic Impact on ATMP Development
The partnership addresses critical manufacturing bottlenecks in the ATMP sector by providing developers with access to state-of-the-art GMP manufacturing space across two major regulatory jurisdictions. By removing barriers in ATMP manufacturing solutions, the collaboration aims to accelerate therapy development timelines and improve global patient access to advanced therapies.
The combined manufacturing capacity and regulatory expertise of both organizations creates an unmatched platform to support global clients in scaling their advanced therapy programs. This transatlantic approach enables more efficient multinational clinical trial execution and commercial launch strategies for ATMP developers seeking to reach patients in both U.S. and European markets.
